Antengene Licenses ATG-106 to K2 Therapeutics, Grants Option Rights

Antengene announced on June 22, 2026, it has licensed its drug candidate ATG-106 to K2 Therapeutics. The agreement also includes granting K2 Therapeutics option rights for an undisclosed bispecific T-cell engager (TCE) program. This collaboration aims to advance the development and potential commercialization of these therapeutic assets. The licensing of ATG-106 represents a key strategic move for Antengene, transferring development and commercialization rights for the compound to K2 Therapeutics. The additional option for the bispecific TCE program could further expand K2's pipeline, signaling a significant partnership in the biopharmaceutical sector.